---
title: "Islet autoantibodies identify classical type 1 diabetes in adults progressing to insulin within 3"
id: "medrxiv-18-positive-islet-autoantibodies-confirm-classical-type-1-diabetes-in-patients"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-18-positive-islet-autoantibodies-confirm-classical-type-1-diabetes-in-patients"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.05.26367089v1?rss=1"
published_at: "2026-11-06T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Islet autoantibodies identify classical type 1 diabetes in adults progressing to insulin within 3
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-18-positive-islet-autoantibodies-confirm-classical-type-1-diabetes-in-patients
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.05.26367089v1?rss=1)
- **Published At:** 2026-11-06T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators studied adults initially treated as **type 2 diabetes** who progressed to insulin within 3 years and tested positive for **islet autoantibodies**. The cohort included 86 such participants; comparison groups were classical type 1 (n=499) and type 2 (n=603). - The team compared genetic risk scores for type 1 and type 2 diabetes (**T1DGRS**, **T2DGRS**) and measured prospective loss of **C-peptide** over three years after diagnosis. Cross-sectional replication used DARE/GoDARTS data (n=9,466). - Autoantibody-positive early progressors had T1DGRS and T2DGRS values that aligned with the classical type 1 cohort. Reported point estimates and confidence intervals showed no significant difference between early autoantibody-positive progressors and classical type 1 participants for T1DGRS, T2DGRS, and annual urine **C-peptide** creatinine ratio decline. - Autoantibody-positive participants who did not progress to insulin early (n=51) demonstrated genetic and C-peptide features consistent with type 2 diabetes, distinguishing them from early progressors. - Authors replicated findings in large cross-sectional cohorts, and they conclude that positive **islet autoantibodies** in adults with early insulin requirement following initial type 2 management identify individuals with the genotype and beta-cell decline of classical **type 1 diabetes**. - The study supports recent guidance recommending autoantibody testing in adults who progress to insulin within three years, though the report is a preprint and has not been peer reviewed. Data are available on request and the prospective study received NHS Research Ethics Committee approval.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=7X8CXvhG3y0gJxlUL99eY3k2D_N0dmkykpnZhpOFeMQ-1794003100.2696319-1.2.1.1-RPAPe_apx6bmlzht7tsk7Oyo23bU7_0l74v0jTCq_FUAdzp60NycL4XBrI.DzV3T) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.11.05.26367089v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Positive islet autoantibodies confirm classical type 1 diabetes in patients treated as type 2 diabetes who have early progression to insulin Vincent E Simpson, Nicholas John Meyrick Thomas, Anita V Hill, Julieanne Knupp, Timothy J McDonald, [ View ORCID Profile](http://orcid.org/0000-0002-9240-8104)Kashyap A Patel, Jacques A Murray Leech, Beverley M Shields, [ View ORCID Profile](http://orcid.org/0000-0001-9237-8585)Ewan R Pearson, [ View ORCID Profile](http://orcid.org/0000-0002-0883-7599)Angus G Jones doi: https://doi.org/10.64898/2026.11.05.26367089 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Vincent E Simpson 1 Department of Clinical and Biomedical Sciences, University of Exeter, Exeter, UK; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Vincent%2BE%2BSimpson%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Simpson%20VE&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AVincent%2BE%2BSimpson%2B) Nicholas John Meyrick Thomas 1 Department of Clinical and Biomedical Sciences, University of Exeter, Exeter, UK; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Nicholas%2BJohn%2BMeyrick%2BThomas%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Thomas%20NJ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANicholas%2BJohn%2BMeyrick%2BThomas%2B) Anita V Hill 1 Department of Clinical and Biomedical Sciences, University of Exeter, Exeter, UK; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Anita%2BV%2BHill%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hill%20AV&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAnita%2BV%2BHill%2B) Julieanne Knupp 1 Department of Clinical and Biomedical Sciences, University of Exeter, Exeter, UK; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Julieanne%2BKnupp%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Knupp%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJulieanne%2BKnupp%2B) Timothy J McDonald 1 Department of Clinical and Biomedical Sciences, University of Exeter, Exeter, UK; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Timothy%2BJ%2BMcDonald%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=McDonald%20TJ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATimothy%2BJ%2BMcDonald%2B) Kashyap A Patel 2 University of Exeter; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kashyap%2BA%2BPatel%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Patel%20KA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKashyap%2BA%2BPatel%2B) * [ORCID record for Kashyap A Patel](http://orcid.org/0000-0002-9240-8104 "Open in new tab") Jacques A Murray Leech 2 University of Exeter; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jacques%2BA%2BMurray%2BLeech%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Murray%20Leech%20JA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJacques%2BA%2BMurray%2BLeech%2B) Beverley M Shields 2 University of Exeter; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Beverley%2BM%2BShields%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Shields%20BM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABeverley%2BM%2BShields%2B) Ewan R Pearson 3 University of dundee * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ewan%2BR%2BPearson%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Pearson%20ER&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AEwan%2BR%2BPearson%2B) * [ORCID record for Ewan R Pearson](http://orcid.org/0000-0001-9237-8585 "Open in new tab") Angus G Jones 2 University of Exeter; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Angus%2BG%2BJones%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Jones%20AG&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAngus%2BG%2BJones%2B) * [ORCID record for Angus G Jones](http://orcid.org/0000-0002-0883-7599 "Open in new tab") * For correspondence: angus.jones@exeter.ac.uk * [Abstract](https://www.medrxiv.org/content/10.64898/2026.11.05.26367089v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1339749/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.11.05.26367089v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1339749/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.11.05.26367089v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1339749/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.11.05.26367089v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1339749/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.11.05.26367089v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1339749/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.11.05.26367089v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1339749/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Objective: Early progression to insulin following initial management as type 2 diabetes may indicate missed type 1 diabetes. Recent guidelines advise islet-autoantibody testing in all adults who progress to insulin within 3 years, though this has not been directly tested. We aimed to determine whether positive islet autoantibodies in this setting confirm the genetic characteristics and C-peptide progression of classical type 1 diabetes. Research Design and Methods: We compared genetic susceptibility to type 1 and type 2 diabetes (T1DGRS and T2DGRS) and prospectively assessed C-peptide loss over 3 years after diagnosis among islet-autoantibody-positive adults initially treated as having type 2 diabetes (without insulin) who progressed to insulin within 3 years (n=86), versus participants with classical type 1 (n=499) and type 2 (n=603) diabetes. Results were replicated in cross-sectional data from the DARE/GoDARTS studies (n=9466). Results: Participants who progressed to insulin within 3 years and had positive islet autoantibodies had the genetic characteristics and C-peptide loss of classical type 1 diabetes: T1DGRS -0.04 (-0.27, 0.18) vs 0.00 (-0.09, 0.09) [p=0.71], T2DGRS -0.35 (-0.59, -0.11) vs -0.35 (-0.44, -0.26) [p=0.99] and annual change in urine C-peptide creatinine ratio -47% (-55%, -40%) vs -49% (-52%, -46%) [p=0.6] respectively. In contrast, autoantibody-positive participants without early insulin (n=51) had genetic and C-peptide characteristics consistent with type 2 diabetes. Findings were similar in cross-sectional cohorts. Conclusion: Islet-autoantibody-positive individuals with early insulin requirement following initial treatment as type 2 diabetes have similar genotype and progression to classical type 1 diabetes. This supports recent guidance that they should be diagnosed and treated as type 1 diabetes. ### Competing Interest Statement NT has received travel support, speaker fees and reimbursement for advisory board membership from Sanofi. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The StartRight study was approved by the South West (Cornwall & Plymouth) NHS Research Ethics Committee on 06/06/2016, ref: 16/SW/0130. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability Data are available upon reasonable request to the authors. ## Funder Information Declared National Institute of Health and Care Research (NIHR), CS-2015-15-018 Diabetes UK, 17/0005624 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.11.05.26367089v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.11.04.26367313v1 "Optimizing Lumipulse plasma pTau217/Aβ42 ratio cutpoints in an Asian cohort with high cerebrovascular disease burden")[Next ](https://www.medrxiv.org/content/10.64898/2026.11.05.26367349v1 "Trends in gout management before and after publication of NICE guidance in England: a population-based study in OpenSAFELY") Posted November 06, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.11.05.26367089v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/11/06/2026.11.05.26367089.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.11.05.26367089v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.11.05.26367089v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/11/06/2026.11.05.26367089.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Positive islet autoantibodies confirm classical type 1 diabetes in patients treated as type 2 diabetes who have early progression to insulin Vincent E Simpson, Nicholas John Meyrick Thomas, Anita V Hill, Julieanne Knupp, Timothy J McDonald, Kashyap A Patel, Jacques A Murray Leech, Beverley M Shields, Ewan R Pearson, Angus G Jones medRxiv 2026.11.05.26367089; doi: https://doi.org/10.64898/2026.11.05.26367089 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.05.26367089v1%26text%3DPositive%2520islet%2520autoantibodies%2520confirm%2520classical%2520type%25201%2520diabetes%2520in%2520patients%2520treated%2520as%2520type%25202%2520diabetes%2520who%2520have%2520early%2520progression%2520to%2520insulin "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.05.26367089v1%26t%3DPositive%2520islet%2520autoantibodies%2520confirm%2520classical%2520type%25201%2520diabetes%2520in%2520patients%2520treated%2520as%2520type%25202%2520diabetes%2520who%2520have%2520early%2520progression%2520to%2520insulin "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.05.26367089v1%26title%3DPositive%2520islet%2520autoantibodies%2520confirm%2520classical%2520type%25201%2520diabetes%2520in%2520patients%2520treated%2520as%2520type%25202%2520diabetes%2520who%2520have%2520early%2520progression%2520to%2520insulin%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.05.26367089v1%26title%3DPositive%2520islet%2520autoantibodies%2520confirm%2520classical%2520type%25201%2520diabetes%2520in%2520patients%2520treated%2520as%2520type%25202%2520diabetes%2520who%2520have%2520early%2520progression%2520to%2520insulin "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.11.05.26367089) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (638) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (917) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (350) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (5002) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (495) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (428) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (676) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1691) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16255) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (36) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1241) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7278) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (751) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1093) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5286) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1467) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1832) * [Hematology](https://www.medrxiv.org/collection/hematology) (599) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1381) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16487) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1203) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (700) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (156) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (751) * [Neurology](https://www.medrxiv.org/collection/neurology) (7592) * [Nursing](https://www.medrxiv.org/collection/nursing) (377) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1129) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1295) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-
## Related Clinical Research

- [Preconception, Gestational, and Postpartum Care for Type 2 Diabetes](https://medichelpline.com/clinical-feed/endocrine-news-0-preconception-gestational-and-postpartum-care.md)
- [Endocrine Society Launches Diabetes SIG and Expands Education, Research, Advocacy](https://medichelpline.com/clinical-feed/endocrine-news-1-society-offers-full-spectrum-of-diabetes-resources-including-a-new-sig-for.md)
- [Antidiabetic regimens and risk of cognitive disorders in type 2 diabetes: large retrospective coho](https://medichelpline.com/clinical-feed/plos-one-23-antidiabetic-medications-and-risk-of-cognitive-disorders-in-type-2-diabetes-a.md)
- [Diabetes Polygenic Scores Predict C-peptide, Glycemia, and Insulin Use in Atypical Diabetes](https://medichelpline.com/clinical-feed/medrxiv-5-diabetes-polygenic-scores-predict-glycemic-indices-and-insulin-use-in.md)
- [Omnipod 5 Automated Insulin Delivery: 12-Month Extension Outcomes in Adults with Type 1 Diabetes](https://medichelpline.com/clinical-feed/pubmed-42671087.md) (DOI: 10.1002/edm2.70321)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.